The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
News|Events|January 1, 2025
7th Aseptic Processing Summit: June 11–12, 2025
Author(s)Pharmaceutical Technology Editors
The seventh edition of this event will focus on compliance, robotics, and automation.
Dates: June 11–12, 2025
Location: Vienna, Austria
Description: The demand for aseptic manufacturing is on the rise, presenting increasingly complex challenges in processing. Accessing EU GMP Annex 1, pharmaceutical companies face new operational hurdles, necessitating technical and organizational adaptations. At the upcoming 7th Aseptic Processing Summit in June 2025, industry experts will illuminate the requisites for robust aseptic processing, offering targeted implementation strategies.
Registration:
Related to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.